Glenmark enters phase 2 studies for asthma treatment Oglemilast

By Elaine Rigoli

Tampa, Fla., April 27 - Glenmark Pharmaceuticals SA announced that its lead molecule for asthma/chronic obstructive pulmonary disease, Oglemilast (GRC 3886), has entered phase 2 trials.

The phase 2 trials are being conducted in the United States by Glenmark's development partner for Oglemilast in North America, Forest Laboratories, Inc.

Two early phase 2 studies are underway, the company said in a news release.

One study is exploring the effect of Oglemilast in mild asthmatic patients facing an antigen challenge, and the second study is evaluating efficacy of Oglemilast in exercise-induced asthma.

Additional phase 2 studies are planned and are expected to be complete in the second half of 2007, the release said.

Glenmark Pharmaceuticals is a fully integrated, research-based pharmaceutical company with headquarters in Mumbai, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.